This report provides detailed analysis of the current and projected mar-kets for diabetic retinopathy (DR) and diabetic macular edema (DME). The DR population represents more than 5.8 million diagnosed patients in the U.S. with 2.3 million DR patients also suffering from DME.
TreatmentTrends: Diabetic Retinopathy/Diabetic Macular Edema (U.S.) is an annual syndicated report series that offers a snapshot of DR and DME market dynamics and competitive landscape through comprehensive primary research with retinal specialists and general ophthalmologists. The report covers the current use of intravitreal injec-tions, in particular anti-VEGF agents, for the treatment of DME, as well as attitudes and perceptions toward these products, advantages and disadvantages, ideal patient types, barriers to growth, promotional activ-ity, and anticipated use. In addition, respondents are queried about their awareness of and interest in products in development.
Questions Answered in This Report:
- What are the clinical features observed among DR and DME pa-tients?
- How are DR and DME patients currently treated, specifically with in-travitreal anti-VEGF agents?
- What product attributes are most important to retinal specialists/general ophthalmologists when selecting a DME therapy? How do the different intravitreal agents perform against these attributes?
- What are the current Lucentis 0.3 mg promotional and messaging efforts for the treatment of DME?
- How do respondents anticipate treatment approaches changing over the next six months? What factors are driving these trends?
- What is physicians’ current awareness of products in late stage devel-opment for the treatment of DME? Which products do they perceive as offering the most value and what factors drive value for the treat-ment of DME?
Sample Frame & Methodology:
~100 fellowship-trained retinal specialists/general ophthalmologists com-plete a 45-minute online quantitative survey with several open-ended questions for qualitative feedback
To qualify, respondents must meet the following criteria:
Minimum of 20 patients with DME under management
Personally administer intravitreal injections to their DME patients
Have been in practice a minimum of 2 years and a maximum of 35 years
More than 75% of professional time spent in clinical practice
Key Drugs Covered:
Avastin, Eylea, Lucentis, Macugen, Ozurdex, Retisert, Kenalog, Triesence, Trivaris, triamcinolone, Iluvien, Optina
Key Companies Mentioned:
Alcon Allergan Alimera Ampio Pharmaceuticals Bausch & Lomb Bristol-Myers Squibb Eyetech Genentech pSivida Regeneron, Roche
- Final report in Powerpoint format
- Complete set of frequency tables, summary statistics, and cross tabulations can be provided upon request
- Proprietary question slide deck: Clients purchasing report prior to fielding will have the opportunity to include up to three proprietary questions
- TreatmentTrends®: Dry/Wet AMD (U.S.) 2014
- TreatmentTrends®: Dry/Wet AMD (EU) 2014
- ChartTrends®: Wet AMD (U.S.) 2013
- DecisionBase®: Wet AMD 2014
- DecisionBase®: Dry AMD 2014
- Physician and Payer Forum®: Wet AMD (U.S.) 2014
- Physician and Payer Forum®: Wet AMD (EU) 2014
- Pharmacor®: AMD 2014
- PatientBase®: Dry/Wet AMD 2014
- PatientBase®: Diabetic Retinopathy 2014
- PatientBase®: Diabetic Macular Edema 2014
- PatientBase®: Retinal Vein Occlusion 2014